Results 291 to 300 of about 101,444 (326)
Some of the next articles are maybe not open access.
Current Diabetes Reports, 2001
Numerous prospective cohort studies have indicated that diabetes mellitus (DM), particularly type-2 DM (the type of diabetes associated with insulin resistance that usually strikes adults), is associated with a 3-4-fold increase in risk for coronary heart disease (CHD) [1-3].
H N, Ginsberg, C, Tuck
openaire +3 more sources
Numerous prospective cohort studies have indicated that diabetes mellitus (DM), particularly type-2 DM (the type of diabetes associated with insulin resistance that usually strikes adults), is associated with a 3-4-fold increase in risk for coronary heart disease (CHD) [1-3].
H N, Ginsberg, C, Tuck
openaire +3 more sources
Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias.
Current pharmaceutical design, 2019Coronary heart disease (CHD) remains the leading cause of disability and death in industrialized Countries. Among many conditions, which contribute to the etiology and progression of CHD, the presence of high low density lipoprotein-cholesterol (LDL-C ...
Michele Scognamiglio +3 more
semanticscholar +1 more source
Atherosclerosis Supplements, 2002
By the year 2025, there will be more than 300 million type 2 diabetes sufferers worldwide. This epidemic will be followed by a wave of cardiovascular disease. Diabetes is in fact a serious vascular disease with poor prognosis, and not only a disease characterized by elevated blood glucose.
openaire +2 more sources
By the year 2025, there will be more than 300 million type 2 diabetes sufferers worldwide. This epidemic will be followed by a wave of cardiovascular disease. Diabetes is in fact a serious vascular disease with poor prognosis, and not only a disease characterized by elevated blood glucose.
openaire +2 more sources
Dyslipidemias and Microcirculation.
Current pharmaceutical design, 2018Dyslipidemia is widely accepted as one of the major risk factors in cardiovascular disease mainly due to its contribution in the pathogenesis of atherosclerosis in medium-sized and large arteries.
T. Padró, G. Vilahur, L. Badimón
semanticscholar +1 more source
2012
Abstract Abnormal cholesterol and lipoprotein metabolism, together with endothelial injury are the major progenitors of atherosclerosis, the leading cause of obstructive coronary artery and vascular diseases worldwide. Dyslipidemia in particular is considered an essential risk factor because atherosclerotic plaques are formed in large ...
Joseph G. Murphy +2 more
+4 more sources
Abstract Abnormal cholesterol and lipoprotein metabolism, together with endothelial injury are the major progenitors of atherosclerosis, the leading cause of obstructive coronary artery and vascular diseases worldwide. Dyslipidemia in particular is considered an essential risk factor because atherosclerotic plaques are formed in large ...
Joseph G. Murphy +2 more
+4 more sources
The American Journal of Cardiology, 1998
Usual risk factors for coronary artery disease account for only 25-50% of increased atherosclerotic risk in diabetes mellitus. Other obvious risk factors are hyperglycemia and dyslipidemia. However, hyperglycemia is a very late stage in the sequence of events from insulin resistance to frank diabetes, whereas lipoprotein abnormalities are manifested ...
openaire +2 more sources
Usual risk factors for coronary artery disease account for only 25-50% of increased atherosclerotic risk in diabetes mellitus. Other obvious risk factors are hyperglycemia and dyslipidemia. However, hyperglycemia is a very late stage in the sequence of events from insulin resistance to frank diabetes, whereas lipoprotein abnormalities are manifested ...
openaire +2 more sources
Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.
Maturitas, 2020P. Anagnostis +14 more
semanticscholar +1 more source
Advances in biological therapies for dyslipidemias and atherosclerosis.
Metabolism: Clinical and Experimental, 2020Eftaxia-Konstantina Valanti +5 more
semanticscholar +1 more source
Polygenic influences on dyslipidemias
Current Opinion in Lipidology, 2018J. Dron, R. Hegele
semanticscholar +1 more source
Role of DNA copy number variation in dyslipidemias
Current Opinion in Lipidology, 2018M. Iacocca, R. Hegele
semanticscholar +1 more source